**Abstract**

Growing evidence supports the notion that sex steroids, particularly estrogen, play an important role in psychiatric disorders. Estrogen mainly acts through estrogen responsive elements on gene promotors to change gene expression. The impact of estrogen on gene expression in the frontal cortex, a region particularly affected in psychiatric disorders, is unknown. This study aimed to identify alterations in gene expression caused by sex steroid hormone removal and estrogen treatment.

Adult female Sprague-Dawley rats were either intact (sham-operated), ovariectomised, or ovariectomised and treated with 17β-estradiol for 4 weeks. Frontal cortical RNA was extracted and purified using the Qiagen RNeasy kit. The samples were hybridised to an Agilent SurePrint G3 Rat Gene Expression microarray. Using JMP Genomics 6.1, quality controls were checked and the expression data analyzed to identify genes with different expression profiles. The genes with different profiles were imported into Ingenuity Pathway Analysis to identify pathways affected by ovariectomy and/or estrogen treatment.

Ovariectomy significantly altered the expression profiles of 145 genes, while estrogen treatment altered the expression profiles of 332 genes. Compared to ovariectomised rats, estrogen-treated rats showed changes in gene expression patterns predicted to affect the activity of translation initiation and elongation (*p*\<0.001) as well as the downstream effects of the master regulator, mechanistic target of rapamycin (mTOR; *p*=0.002).

Importantly, while there was some overlap in altered expression profiles between the ovariectomised animals and those receiving estrogen, these results highlight that removal of sex steroids by ovariectomy substantially differs from estrogen treatment. These data suggest that the effects on translation and mTOR, combined with the effect of estrogen at estrogen responsive elements will have profound and wide-ranging effects in the frontal cortex. This supports the concept that sex steroids play a role on modulating pathways associated with psychosis and schizophrenia, including several neurotransmitter systems (e.g. dopamine, serotonin, noradrenaline, glutamate).
